Antioxidant Treatment of Type 2 Diabetes

Early Phase 1CompletedNCT00609102

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)44 enrolled

Overview

This study examines whether an antioxidant taken orally will improve glucose tolerance and insulin secretion in type 2 diabetic subjects.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

one capsule BID

450 mgm BID

Sex: ALLMin age: 18 YearsMax age: 70 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: Subjects with a known diagnosis of type 2 diabetes - Exclusion Criteria: None, except known intolerance to n-acetylcysteine \-

Pacific Northwest Research Institute

Seattle, Washington, United States

Blood glucose

Time frame: 3 months

HbA1c levels

Time frame: 3 months

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.